Date | Price Target | Rating | Analyst |
---|---|---|---|
9/10/2024 | Peer Perform | Wolfe Research | |
7/1/2024 | $140.00 → $115.00 | Overweight → Neutral | Piper Sandler |
5/30/2024 | $129.00 | Neutral | Goldman |
5/21/2024 | $150.00 | Hold → Buy | Argus |
1/4/2024 | $135.00 → $125.00 | Outperform → In-line | Evercore ISI |
10/20/2023 | $120.00 | Neutral | ROTH MKM |
8/28/2023 | $139.00 | Neutral → Buy | BTIG Research |
5/3/2023 | Underperform → Neutral | BofA Securities |
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
424B5 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
WARSAW, Ind., Sept. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that David DeMartino will join the Company as Senior Vice President, Investor Relations, effective September 9, 2024. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. DeMartino will be responsible for developing, refining and leading Zimmer Biomet's investor relations strategy and cultivating relationships with the investment and financial community. "We are excited to welcome David to Zimmer Bi
WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
WARSAW, Ind., Aug. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will present at two upcoming healthcare conferences in September. The team will be presenting at the Wells Fargo 2024 Healthcare Conference on Thursday, September 5, 2024, at 8:00 a.m. ET. Subsequently, the team will present at the Morgan Stanley Annual Global Healthcare Conference on Friday, September 6, 2024, at 9:15 a.m. ET. A live webcast of the presentations can be accessed via Z
Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform
Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously
Goldman initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $129.00
Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price target from $130 to $117.
Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight and lowers the price target from $130 to $120.
Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $134 to $120.
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su
Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay's Role Expands to CFO and EVP, Finance, Operations & Supply Chain Company Reaffirms Full-Year 2023 Financial Guidance WARSAW, Ind., Aug. 22, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basisSecond quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidanceWARSAW, Ind., Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024. The Company reported second quarter net sales of $1.942 billion, an increase of 3.9% over the prior year period, and an increase of 5.6% on a constant curren
WARSAW, Ind., July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s